de Jonge, Maja J A <br/><br/>
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  May 2005 
 - 3806-13 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-04-1937  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Chromatography, High Pressure Liquid<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Oligopeptides--administration & dosage